Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vickerman

Showing results (91-100 of 397) with videos related to

Pageof 40
Sort By:
Epidemics|February 27, 2013
A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspectiveAmparo Yovanna Castro Sanchez, Marc Aerts, Ziv Shkedy, et al.
AIDS (London, England)|December 23, 2008
The impact of out-migrants and out-migration on the HIV/AIDS epidemic: a case study from south-west IndiaKathleen N Deering, Peter Vickerman, Stephen Moses, et al.
Health Economics|January 15, 2016
What Determines HIV Prevention Costs at Scale? Evidence from the Avahan Programme in IndiaAurélia Lépine, Sudhashree Chandrashekar, Govindraj Shetty, et al.
Plos One|February 6, 2013
The impact of syphilis screening among female sex workers in China: a modelling studyKate M Mitchell, Andrew P Cox, David Mabey, et al.
The Journal of Antimicrobial Chemotherapy|November 30, 2019
The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UKZoe Ward, Linda Campbell, Julian Surey, et al.
Sexually Transmitted Diseases|June 1, 2006
The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, UkrainePeter Vickerman, Lilani Kumaranayake, Olga Balakireva, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 24, 2020
An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United KingdomJack Williams, Peter Vickerman, Sam Douthwaite, et al.
BMJ Open|July 1, 2019
Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluationNatasha K Martin, Peter Vickerman, Salim Khakoo, et al.
The Lancet. HIV|December 4, 2024
HIV incidence and factors associated with HIV risk among people who inject drugs engaged with harm-reduction programmes in four provinces in South Africa: a retrospective cohort studyAdelina Artenie, Rachel Perry, Memory Mahaso, et al.
BMC Global and Public Health|December 16, 2024
Modelling COVID-19 transmission dynamics in Laos under non-pharmaceutical interventions, vaccination, and replacement of SARS-CoV-2 variantsXu-Sheng Zhang, Hong Luo, Andre Charlett, et al.
Pageof 40

Showing results (91-100 of 397) with videos related to

Sort By:
Pageof 40
Epidemics|February 27, 2013
A mathematical model for HIV and hepatitis C co-infection and its assessment from a statistical perspectiveAmparo Yovanna Castro Sanchez, Marc Aerts, Ziv Shkedy, et al.
AIDS (London, England)|December 23, 2008
The impact of out-migrants and out-migration on the HIV/AIDS epidemic: a case study from south-west IndiaKathleen N Deering, Peter Vickerman, Stephen Moses, et al.
Health Economics|January 15, 2016
What Determines HIV Prevention Costs at Scale? Evidence from the Avahan Programme in IndiaAurélia Lépine, Sudhashree Chandrashekar, Govindraj Shetty, et al.
Plos One|February 6, 2013
The impact of syphilis screening among female sex workers in China: a modelling studyKate M Mitchell, Andrew P Cox, David Mabey, et al.
The Journal of Antimicrobial Chemotherapy|November 30, 2019
The cost-effectiveness of an HCV outreach intervention for at-risk populations in London, UKZoe Ward, Linda Campbell, Julian Surey, et al.
Sexually Transmitted Diseases|June 1, 2006
The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, UkrainePeter Vickerman, Lilani Kumaranayake, Olga Balakireva, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 24, 2020
An Economic Evaluation of the Cost-Effectiveness of Opt-Out Hepatitis B and Hepatitis C Testing in an Emergency Department Setting in the United KingdomJack Williams, Peter Vickerman, Sam Douthwaite, et al.
BMJ Open|July 1, 2019
Chronic hepatitis B virus case-finding in UK populations born abroad in intermediate or high endemicity countries: an economic evaluationNatasha K Martin, Peter Vickerman, Salim Khakoo, et al.
The Lancet. HIV|December 4, 2024
HIV incidence and factors associated with HIV risk among people who inject drugs engaged with harm-reduction programmes in four provinces in South Africa: a retrospective cohort studyAdelina Artenie, Rachel Perry, Memory Mahaso, et al.
BMC Global and Public Health|December 16, 2024
Modelling COVID-19 transmission dynamics in Laos under non-pharmaceutical interventions, vaccination, and replacement of SARS-CoV-2 variantsXu-Sheng Zhang, Hong Luo, Andre Charlett, et al.
Pageof 40